Potential impact of selinesol tablets treatment on patient lifespan

Selinexor is a pioneering oral selective nuclear export inhibitor (SINE). Its unique mechanism of action brings new hope for tumor treatment. The drug can tightly bind to the nuclear export protein XPO1, thereby inhibiting its normal function, leading to the gradual accumulation of tumor suppressor proteins inside the nucleus. This process not only reactivates the function of the tumor suppressor protein, but also significantly amplifies its inhibitory effect on cancer cells while minimizing damage to normal cells.

The U.S. Food and Drug Administration (FDA) has approved for the first time selinexol in combination with dexamethasone for the treatment of heavily pretreated myeloma patients. The decision was based on a clinical trial called STORM, which delved into the efficacy of selinesol in the treatment of relapsed myeloma. Among them, 53% had high-risk cytogenetic abnormalities. After treatment with selinesol, 26% of patients achieved partial remission or better, and two patients even achieved strict complete remission criteria. Overall, the clinical benefit rate reached 39%. Among those who achieved response, the median duration of response was 4.4 months, the median progression-free survival was 3.7 months, and the median overall survival was 8.6 months. For those patients who achieved molecular response or better, their median overall survival was extended to 15.6 months.

Although the main goals of drug therapy are to control cancer progression and improve patients' quality of life, the question of whether drugs extend patients' lives involves numerous complex factors. The patient's overall health, age, comorbidities, treatment options chosen, and medical environment all have an impact on survival. Therefore, when using selinesol tablets for treatment, whether it can prolong the patient's life needs to be comprehensively evaluated based on the patient's specific situation and the type of disease he suffers from.